ArticleFrontiers in cellular and infection microbiology2026
Impact of continuous probiotic supplementation on intestinal barrier function and hepatic biomarkers in fulminant liver failure models.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiota modulation in the prevention and treatment of heat stroke.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fulminant liver failure (FLF) is characterized by sudden hepatocellular necrosis, severe systemic inflammation, and rapid progression to multiorgan failure. Increasing evidence implicates intestinal barrier dysfunction and microbe-associated molecular pattern (MAMP) translocation as key drivers of hepatic injury through gut-liver axis dysregulation. Probiotic-mediated modulation of epithelial integrity and mucosal immunity has shown promise; however, available data in FLF settings remain limited. Objectives: This study examined whether continuous probiotic supplementation modulates intestinal epithelial barrier function, limits bacterial translocation, and reduces biochemical and histopathological indicators of hepatic damage in d-galactosamine/lipopolysaccharide (GalN/LPS)-induced FLF models. Methods: Male Wistar rats were randomized into three groups: (i) healthy controls, (ii) FLF (700 mg/kg GalN + 10 µg/kg LPS, intraperitoneal), and (iii) FLF + probiotics. Animals in the probiotic group received a multistrain probiotic formulation ( Results: Probiotic supplementation markedly reduced GalN/LPS-induced intestinal hyperpermeability ( Conclusion: Continuous probiotic administration provides critical protection against FLF by fortifying epithelial tight junction integrity, suppressing gut-derived inflammatory signaling, and limiting hepatocellular damage. These findings support the utility of targeted microbiota-directed interventions as adjunctive preclinical therapeutic strategies for acute liver failure and warrant further translational evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.